These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34615706)

  • 1. Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer.
    Zhou YF; Xiao Y; Jin X; Di GH; Jiang YZ; Shao ZM
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34615706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HLA-I landscape confers prognosis and antitumor immunity in breast cancer.
    Ding XH; Xiao Y; Chen F; Liu CL; Fu T; Shao ZM; Jiang YZ
    Brief Bioinform; 2024 Mar; 25(3):. PubMed ID: 38602320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.
    Karn T; Jiang T; Hatzis C; Sänger N; El-Balat A; Rody A; Holtrich U; Becker S; Bianchini G; Pusztai L
    JAMA Oncol; 2017 Dec; 3(12):1707-1711. PubMed ID: 28750120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of Human Leukocyte Antigen and Immune Escape in Head and Neck Cancer.
    Morris LGT
    Laryngoscope; 2024 Jan; 134(1):160-165. PubMed ID: 37249223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A machine learning algorithm with subclonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygosity.
    Pyke RM; Mellacheruvu D; Dea S; Abbott CW; McDaniel L; Bhave DP; Zhang SV; Levy E; Bartha G; West J; Snyder MP; Chen RO; Boyle SM
    Nat Commun; 2022 Apr; 13(1):1925. PubMed ID: 35414054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response.
    Montesion M; Murugesan K; Jin DX; Sharaf R; Sanchez N; Guria A; Minker M; Li G; Fisher V; Sokol ES; Pavlick DC; Moore JA; Braly A; Singal G; Fabrizio D; Comment LA; Rizvi NA; Alexander BM; Frampton GM; Hegde PS; Albacker LA
    Cancer Discov; 2021 Feb; 11(2):282-292. PubMed ID: 33127846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological and clinical significance of loss of heterozygosity at the INPP4B gene locus in Japanese breast cancer.
    Tokunaga E; Yamashita N; Kitao H; Tanaka K; Taketani K; Inoue Y; Saeki H; Oki E; Oda Y; Maehara Y
    Breast; 2016 Feb; 25():62-8. PubMed ID: 26577950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15.
    Garrido MA; Rodriguez T; Zinchenko S; Maleno I; Ruiz-Cabello F; Concha Á; Olea N; Garrido F; Aptsiauri N
    Immunogenetics; 2018 Nov; 70(10):647-659. PubMed ID: 30145665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.
    McGranahan N; Rosenthal R; Hiley CT; Rowan AJ; Watkins TBK; Wilson GA; Birkbak NJ; Veeriah S; Van Loo P; Herrero J; Swanton C;
    Cell; 2017 Nov; 171(6):1259-1271.e11. PubMed ID: 29107330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High level of aneuploidy of chromosome 6 by FISH analysis of head and neck squamous cell carcinoma: limited applicability of LOH analysis to define HLA loss.
    Koene GJ; Arts-Hilkes YH; van Dijk AJ; van der Ven KJ; Slootweg PJ; de Weger RA; Tilanus MG
    Hum Immunol; 2004 Dec; 65(12):1455-62. PubMed ID: 15603873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Characteristics of Lymphocyte-predominant Triple-negative Breast Cancer.
    Sasaki R; Horimoto Y; Yanai Y; Kurisaki-Arakawa A; Arakawa A; Nakai K; Saito M; Saito T
    Anticancer Res; 2021 Apr; 41(4):2133-2140. PubMed ID: 33813424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.
    Ma D; Jiang YZ; Xiao Y; Xie MD; Zhao S; Jin X; Xu XE; Shao ZM
    Cancer; 2020 Jul; 126(14):3209-3218. PubMed ID: 32383785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated investigation of the prognostic role of HLA LOH in advanced lung cancer patients with immunotherapy.
    Zhang X; Tang H; Luo H; Lu H; Pan C; Yu H; Zhang L; Guan Y; Yu L; Chu H; Chen J; Wang J
    Front Genet; 2022; 13():1066636. PubMed ID: 36531232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
    Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
    Telli ML; Timms KM; Reid J; Hennessy B; Mills GB; Jensen KC; Szallasi Z; Barry WT; Winer EP; Tung NM; Isakoff SJ; Ryan PD; Greene-Colozzi A; Gutin A; Sangale Z; Iliev D; Neff C; Abkevich V; Jones JT; Lanchbury JS; Hartman AR; Garber JE; Ford JM; Silver DP; Richardson AL
    Clin Cancer Res; 2016 Aug; 22(15):3764-73. PubMed ID: 26957554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
    Domagala P; Hybiak J; Cybulski C; Lubinski J
    Int J Cancer; 2017 Apr; 140(7):1545-1550. PubMed ID: 27943282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers.
    Abdel-Fatah TM; Arora A; Moseley PM; Perry C; Rakha EA; Green AR; Chan SY; Ellis IO; Madhusudan S
    Oncotarget; 2015 Sep; 6(26):21964-78. PubMed ID: 26267318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cancer-testis gene,
    Gu Y; Wang C; Zhu R; Yang J; Yuan W; Zhu Y; Zhou Y; Qin N; Shen H; Ma H; Wang H; Liu X; Hu Z
    Cancer Biol Med; 2021 Feb; 18(1):74-87. PubMed ID: 33628586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of heterozygosity at 6p21.3 underlying HLA class I downregulation in gastric cancer.
    Wang XC; Zhang JQ; Shen YQ; Miao FQ; Xie W
    J Exp Clin Cancer Res; 2006 Mar; 25(1):115-9. PubMed ID: 16761627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CLImAT-HET: detecting subclonal copy number alterations and loss of heterozygosity in heterogeneous tumor samples from whole-genome sequencing data.
    Yu Z; Li A; Wang M
    BMC Med Genomics; 2017 Mar; 10(1):15. PubMed ID: 28298214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.